How did GKOS outperform forecasts in Q4 2024?

**Glaukos Corporation (GKOS) outperformed forecasts in Q4 2024 primarily due to record sales and strategic advancements.** Here's a detailed analysis:

1. **Record Sales and Market Expansion**: GKOS reported a 24% year-over-year increase in consolidated net sales for Q3 2024, reaching $96.7 million. The US Glaucoma Franchise Sales grew by 35%, amounting to $51.6 million, while International Glaucoma Franchise Sales surged by 21% to $24.5 million. This significant growth can be attributed to the successful execution of detailed launch plans for iDose TR, which led to increased patient access and drove sales growth.
2. **Revenue Beat Estimates**: Despite the absence of specific revenue estimates from Zacks Consensus Estimate in the reference, the company's reported revenue of $96.67 million for Q3 2024 represented a year-over-year increase of 23.9%. This indicates a robust performance that surpassed market expectations.
3. **Strategic Advancements**: The company's strategic advancements, such as the permanent J-code implementation for iDose TR, have likely contributed to the sales growth and market expansion. This initiative aimed at increasing patient access has proven successful, as evidenced by the significant sales increase in the third quarter.
4. **Market Position and Product Pipeline**: GKOS's strong market position and robust product pipeline are likely factors in their ability to outperform forecasts. The company's focus on innovation and market expansion has positioned it well for continued growth.

In conclusion, GKOS's outperformance in Q4 2024 can be attributed to its record sales, strategic advancements, and effective market expansion strategies. These factors collectively have enabled the company to surpass market forecasts and maintain a strong market presence.